Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease

  1. Carl R. Walkley1,8,
  2. Rameez Qudsi1,
  3. Vijay G. Sankaran1,
  4. Jennifer A. Perry1,
  5. Monica Gostissa2,
  6. Sanford I. Roth3,
  7. Stephen J. Rodda4,
  8. Erin Snay5,
  9. Patricia Dunning6,
  10. Frederic H. Fahey5,
  11. Frederick W. Alt2,
  12. Andrew P. McMahon4, and
  13. Stuart H. Orkin1,7,9
  1. 1 Department of Pediatric Oncology, Dana-Farber Cancer Institute, Division of Hematology/Oncology and Stem Cell Program, Children’s Hospital Boston, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts 02115, USA;
  2. 2 Howard Hughes Medical Institute, The Children’s Hospital, Department of Genetics, Harvard Medical School and Immune Disease Institute, Boston, Massachusetts 02115, USA;
  3. 3 Department of Pathology, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts 02114, USA;
  4. 4 Department of Molecular and Cellular Biology, Harvard University, Cambridge, Massachusetts 02138, USA;
  5. 5 Division of Nuclear Medicine, Children’s Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA;
  6. 6 Department of Radiology, Children’s Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA;
  7. 7 Howard Hughes Medical Institute, Boston, Massachusetts 02115, USA

Abstract

Osteosarcoma is the most common primary malignant tumor of bone. Analysis of familial cancer syndromes and sporadic cases has strongly implicated both p53 and pRb in its pathogenesis; however, the relative contribution of these mutations to the initiation of osteosarcoma is unclear. We describe here the generation and characterization of a genetically engineered mouse model in which all animals develop short latency malignant osteosarcoma. The genetically engineered mouse model is based on osteoblast-restricted deletion of p53 and pRb. Osteosarcoma development is dependent on loss of p53 and potentiated by loss of pRb, revealing a dominance of p53 mutation in the development of osteosarcoma. The model reproduces many of the defining features of human osteosarcoma including cytogenetic complexity and comparable gene expression signatures, histology, and metastatic behavior. Using a novel in silico methodology termed cytogenetic region enrichment analysis, we demonstrate high conservation of gene expression changes between murine osteosarcoma and known cytogentically rearranged loci from human osteosarcoma. Due to the strong similarity between murine osteosarcoma and human osteosarcoma in this model, this should provide a valuable platform for addressing the molecular genetics of osteosarcoma and for developing novel therapeutic strategies.

Keywords

Footnotes

  • 8 Present address: St. Vincent’s Institute of Medical Research, Fitzroy, Victoria 3065, Australia.

  • 9 Corresponding author.

    9 E-MAIL Stuart_Orkin{at}dfci.harvard.edu; FAX (617) 632-4367.

  • Supplemental material is available at http://www.genesdev.org.

  • Article is online at http://www.genesdev.org/cgi/doi/10.1101/gad.1656808.

    • Received January 29, 2008.
    • Accepted April 21, 2008.
| Table of Contents

Life Science Alliance